IDXX has been the subject of several other reports. Canaccord Genuity reiterated a buy rating and issued a $120.00 target price on shares of Idexx Laboratories in a report on Monday, August 22nd. Stifel Nicolaus raised their target price on shares of Idexx Laboratories from $120.00 to $125.00 and gave the stock a buy rating in a report on Tuesday, August 16th. Zacks Investment Research cut shares of Idexx Laboratories from a buy rating to a hold rating in a report on Monday, July 4th. Finally, Northcoast Research upgraded shares of Idexx Laboratories from a sell rating to a neutral rating in a report on Wednesday, August 3rd. Five research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company presently has an average rating of Buy and an average target price of $105.20.
Shares of Idexx Laboratories (NASDAQ:IDXX) opened at 112.93 on Thursday. The firm’s 50-day moving average is $111.64 and its 200 day moving average is $94.79. Idexx Laboratories has a 1-year low of $63.48 and a 1-year high of $115.06. The stock has a market capitalization of $10.11 billion, a P/E ratio of 51.19 and a beta of 0.41.
Idexx Laboratories (NASDAQ:IDXX) last announced its earnings results on Tuesday, August 2nd. The company reported $0.74 EPS for the quarter, topping the consensus estimate of $0.62 by $0.12. Idexx Laboratories had a net margin of 11.94% and a negative return on equity of 414.67%. The company earned $467 million during the quarter, compared to analysts’ expectations of $444.83 million. During the same period last year, the company posted $0.60 earnings per share. The business’s revenue for the quarter was up 12.9% on a year-over-year basis. On average, analysts expect that Idexx Laboratories will post $2.36 EPS for the current fiscal year.
In related news, Director Rebecca M. Henderson sold 9,924 shares of the firm’s stock in a transaction that occurred on Thursday, August 25th. The shares were sold at an average price of $110.43, for a total transaction of $1,095,907.32. Following the transaction, the director now owns 16,678 shares of the company’s stock, valued at $1,841,751.54. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director William T. End sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, August 5th. The shares were sold at an average price of $108.50, for a total transaction of $542,500.00. Following the transaction, the director now directly owns 53,564 shares in the company, valued at approximately $5,811,694. The disclosure for this sale can be found here. 2.79% of the stock is currently owned by insiders.
A number of institutional investors have recently modified their holdings of IDXX. Menta Capital LLC acquired a new position in shares of Idexx Laboratories during the first quarter valued at $1,143,000. C M Bidwell & Associates Ltd. raised its position in shares of Idexx Laboratories by 1,059.3% in the first quarter. C M Bidwell & Associates Ltd. now owns 46,545 shares of the company’s stock valued at $3,645,000 after buying an additional 42,530 shares during the last quarter. BlackRock Group LTD raised its position in shares of Idexx Laboratories by 70.8% in the first quarter. BlackRock Group LTD now owns 130,048 shares of the company’s stock valued at $10,185,000 after buying an additional 53,887 shares during the last quarter. BlackRock Inc. raised its position in shares of Idexx Laboratories by 20.7% in the first quarter. BlackRock Inc. now owns 39,545 shares of the company’s stock valued at $3,098,000 after buying an additional 6,777 shares during the last quarter. Finally, Franklin Resources Inc. raised its position in shares of Idexx Laboratories by 36.9% in the first quarter. Franklin Resources Inc. now owns 410,613 shares of the company’s stock valued at $32,159,000 after buying an additional 110,604 shares during the last quarter. 91.58% of the stock is currently owned by hedge funds and other institutional investors.
Idexx Laboratories Company Profile
Receive News & Ratings for Idexx Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idexx Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.